Recent Advances in Adult Acute Lymphoblastic Leukemia.
Adult
Antibodies, Bispecific
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Arabinonucleosides
/ administration & dosage
Humans
Immunotherapy
/ methods
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
/ diagnosis
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
/ diagnosis
Rituximab
/ administration & dosage
Stem Cell Transplantation
/ methods
Acute lymphoblastic leukemia
Chimeric antigen receptor T cells
Management
Monoclonal antibodies
Treatment
Journal
Current hematologic malignancy reports
ISSN: 1558-822X
Titre abrégé: Curr Hematol Malig Rep
Pays: United States
ID NLM: 101262565
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
pubmed:
18
3
2019
medline:
7
7
2020
entrez:
18
3
2019
Statut:
ppublish
Résumé
This article reviews the recent advances in the pathophysiology and management of acute lymphoblastic leukemia (ALL) in adults. Addition of rituximab to standard chemotherapy improves survival in the frontline treatment of B cell ALL, and measurable residual disease (MRD) is the most important prognostic factor. Tyrosine kinase inhibitors (TKI), particularly ponatinib, in combination with Hyper-CVAD significantly improve outcomes in Ph + ALL challenging the benefit of allogeneic stem cell transplant in first line for these patients. Blinatumomab, inotuzumab ozogamicin, and chimeric antigen receptor (CAR) T cells are better options than chemotherapy alone for the treatment of relapsed or refractory ALL. Combination of these agents with chemotherapy and their incorporation in the frontline setting show promises to improve cure rates of ALL. Development of monoclonal antibodies, CAR T, and potent TKI has improved the outcome of ALL. Advances in our understanding of ALL biology are expected to bring new therapeutic strategies in the upcoming years.
Identifiants
pubmed: 30879177
doi: 10.1007/s11899-019-00503-1
pii: 10.1007/s11899-019-00503-1
doi:
Substances chimiques
Antibodies, Bispecific
0
Arabinonucleosides
0
Rituximab
4F4X42SYQ6
blinatumomab
4FR53SIF3A
nelarabine
60158CV180
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
106-118Références
Blood. 2012 Aug 30;120(9):1868-76
pubmed: 22442346
Br J Haematol. 2016 Feb;172(3):439-51
pubmed: 26683485
Lancet Oncol. 2015 Jan;16(1):57-66
pubmed: 25524800
J Clin Oncol. 2017 Feb;35(4):394-401
pubmed: 27870571
Blood. 2015 Aug 6;126(6):746-56
pubmed: 26065651
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Blood. 2011 Dec 15;118(25):6521-8
pubmed: 21931113
Blood. 2016 Aug 11;128(6):774-82
pubmed: 27121472
Blood. 2013 Aug 15;122(7):1214-21
pubmed: 23836561
Blood. 2007 Feb 1;109(3):944-50
pubmed: 17032921
Cancer Cell. 2014 Sep 8;26(3):428-442
pubmed: 25132497
J Clin Oncol. 2018 Sep 21;:JCO2017773648
pubmed: 30240326
Cancer. 2013 Aug 1;119(15):2728-36
pubmed: 23633004
Blood. 2007 May 1;109(9):3676-8
pubmed: 17213285
Am J Hematol. 2018 Jan;93(1):91-99
pubmed: 29047158
Blood Cancer J. 2014 Oct 17;4:e252
pubmed: 25325302
Nature. 2008 May 1;453(7191):110-4
pubmed: 18408710
N Engl J Med. 2017 Mar 2;376(9):836-847
pubmed: 28249141
Cancer. 2006 Oct 1;107(7):1551-61
pubmed: 16955505
Lancet Oncol. 2018 Feb;19(2):240-248
pubmed: 29352703
Leukemia. 2004 Dec;18(12):2032-5
pubmed: 15483674
Blood Adv. 2017 Jun 27;1(15):1167-1180
pubmed: 29296758
J Clin Oncol. 2009 Feb 20;27(6):911-8
pubmed: 19124805
J Clin Oncol. 2003 Mar 1;21(5):774-80
pubmed: 12610173
Leukemia. 2009 Aug;23(8):1406-9
pubmed: 19282835
Leuk Lymphoma. 2011 Jun;52(6):1098-107
pubmed: 21348573
Blood. 2018 Jul 26;132(4):385-392
pubmed: 29895664
Cancer Cell. 2012 Aug 14;22(2):153-66
pubmed: 22897847
J Clin Oncol. 2014 Dec 20;32(36):4134-40
pubmed: 25385737
Am J Hematol. 2016 Aug;91(8):819-23
pubmed: 27178680
Cancer. 2017 Feb 1;123(3):459-467
pubmed: 27696391
Blood. 2006 Sep 1;108(5):1469-77
pubmed: 16638934
J Clin Oncol. 2017 Aug 10;35(23):2683-2691
pubmed: 28605290
J Clin Oncol. 2008 Apr 10;26(11):1843-9
pubmed: 18398150
J Immunol. 2006 Jul 1;177(1):362-71
pubmed: 16785532
Lancet Oncol. 2009 Feb;10(2):125-34
pubmed: 19138562
J Clin Oncol. 2014 May 10;32(14):1453-62
pubmed: 24711557
Blood. 2007 Jun 15;109(12):5136-42
pubmed: 17344466
Leukemia. 2007 Sep;21(9):1907-14
pubmed: 17611565
Blood. 2015 Jun 25;125(26):3996-4009
pubmed: 25999452
Blood. 2014 Jun 12;123(24):3739-49
pubmed: 24740809
J Clin Oncol. 2012 Sep 1;30(25):3100-8
pubmed: 22851563
Br J Haematol. 2009 Jun;146(1):76-85
pubmed: 19438471
N Engl J Med. 2016 Aug 25;375(8):740-53
pubmed: 27292104
Cancer. 2009 May 15;115(10):2147-54
pubmed: 19298009
Haematologica. 2010 Feb;95(2):241-6
pubmed: 19713226
Cancer. 2008 Dec 1;113(11):3186-91
pubmed: 18846563
Haematologica. 2016 Dec;101(12):1524-1533
pubmed: 27587380
JAMA Oncol. 2017 Jul 13;3(7):e170580
pubmed: 28494052
Lancet Oncol. 2009 Feb;10(2):147-56
pubmed: 19147408
N Engl J Med. 2009 Jun 25;360(26):2730-41
pubmed: 19553647
Leukemia. 2018 Mar;32(3):606-615
pubmed: 28819280
Blood Adv. 2018 Jul 10;2(13):1522-1531
pubmed: 29954814
Blood. 2012 Sep 6;120(10):2032-41
pubmed: 22493293
Blood. 2009 Dec 10;114(25):5136-45
pubmed: 19828704
Blood. 2010 Sep 23;116(12):2070-7
pubmed: 20466853
Lancet Oncol. 2015 Nov;16(15):1547-1555
pubmed: 26432046
Blood. 2005 Dec 1;106(12):3760-7
pubmed: 16105981
JAMA Oncol. 2018 Feb 1;4(2):230-234
pubmed: 28859185
Pediatr Blood Cancer. 2007 Mar;48(3):254-61
pubmed: 16421910
Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):897-901
pubmed: 28927784
N Engl J Med. 2013 Nov 14;369(20):1915-25
pubmed: 24224624
J Clin Oncol. 2017 Jun 1;35(16):1795-1802
pubmed: 28355115
Blood. 2015 Jun 11;125(24):3711-9
pubmed: 25878120
Blood. 2014 Dec 18;124(26):3870-9
pubmed: 25359988
Blood. 2008 Sep 1;112(5):1646-54
pubmed: 18502832
Blood. 2011 Sep 29;118(13):3504-11
pubmed: 21715318
Cancer. 2014 Dec 15;120(24):3958-64
pubmed: 25116331
Blood. 2004 Sep 15;104(6):1793-800
pubmed: 15172969
Br J Haematol. 2012 Jan;156(2):234-44
pubmed: 22098541
Br J Haematol. 2010 Jan;148(1):80-9
pubmed: 19863538
Blood. 2016 Apr 14;127(15):1863-9
pubmed: 26747249
Blood. 2017 Feb 2;129(5):572-581
pubmed: 27919910
Blood. 2017 Oct 19;130(16):1832-1844
pubmed: 28790105
N Engl J Med. 2014 Mar 20;370(12):1101-10
pubmed: 24401022
Blood. 2009 Jun 18;113(25):6330-7
pubmed: 18703706
Haematologica. 2010 Feb;95(2):324-8
pubmed: 19773266
Blood. 2016 Jul 28;128(4):504-7
pubmed: 27235138
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62
pubmed: 28925994
Cancer. 2006 Apr 1;106(7):1569-80
pubmed: 16502413
Cancer. 2018 Oct 15;124(20):4044-4055
pubmed: 30307611
Haematologica. 2015 May;100(5):653-61
pubmed: 25682595
J Clin Oncol. 2011 Jun 20;29(18):2493-8
pubmed: 21576633
N Engl J Med. 2016 Sep 15;375(11):1044-53
pubmed: 27626518
Lancet. 2016 Jun 11;387(10036):2402-11
pubmed: 27080498
Leukemia. 2015 Mar;29(3):526-34
pubmed: 25079173
N Engl J Med. 2018 Feb 1;378(5):449-459
pubmed: 29385376
Cancer. 2004 Dec 15;101(12):2788-801
pubmed: 15481055
J Clin Oncol. 2013 Dec 1;31(34):4333-42
pubmed: 24166518
Blood. 2007 Apr 15;109(8):3189-97
pubmed: 17170120
J Clin Oncol. 2010 Aug 20;28(24):3880-9
pubmed: 20660823
Blood. 2015 Apr 16;125(16):2486-96; quiz 2586
pubmed: 25587040
Blood. 2014 Feb 6;123(6):843-50
pubmed: 24277073
Blood. 2015 Jun 25;125(26):3977-87
pubmed: 25999453
N Engl J Med. 2014 Sep 11;371(11):1005-15
pubmed: 25207766
Blood. 2018 Apr 5;131(14):1522-1531
pubmed: 29358182
Nature. 2012 Jan 11;481(7380):157-63
pubmed: 22237106